Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 10, 2016 - Issue
Submit an article Journal homepage
98
Views
35
CrossRef citations to date
0
Altmetric
Review

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide

Fabrizio StocchiInstitute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome, ItalyCorrespondence[email protected]
&
Margherita TortiInstitute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome, Italy
Pages 609-618 | Published online: 05 Feb 2016

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Christian Espinoza-Vinces, Rafael Villino-Rodríguez, Ainhoa Atorrasagasti-Villar, Gloria Martí-Andrés & María-Rosario Luquin. (2023) Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease. Patient Related Outcome Measures 14, pages 285-295.
Read now

Articles from other publishers (34)

Subramanian Thangaleela, Bhagavathi Sundaram Sivamaruthi, Periyanaina Kesika, Subramanian Mariappan, Subramanian Rashmi, Thiwanya Choeisoongnern, Phakkharawat Sittiprapaporn & Chaiyavat Chaiyasut. (2023) Neurological Insights into Sleep Disorders in Parkinson’s Disease. Brain Sciences 13:8, pages 1202.
Crossref
Diego Santos García, Iria Cabo López, Carmen Labandeira Guerra, Rosa Yáñez Baña, Maria I. Cimas Hernando, Jose M. Paz González, Maria G. Alonso Losada, Maria J. Gonzalez Palmás, Carlos Cores Bartolomé & Cristina Martínez Miró. (2021) Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study. Neurological Sciences 43:4, pages 2537-2544.
Crossref
Fabrizio Stocchi, Angelo Antonini, Daniela Berg, Bruno Bergmans, Wolfgang Jost, Regina Katzenschlager, Jaime Kulisevsky, Per Odin, Francesc Valldeoriola & K. Ray Chaudhuri. (2022) Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus. npj Parkinson's Disease 8:1.
Crossref
Jeremy Hunt, Elizabeth J. Coulson, Rajendram Rajnarayanan, Henrik Oster, Aleksandar Videnovic & Oliver Rawashdeh. (2022) Sleep and circadian rhythms in Parkinson’s disease and preclinical models. Molecular Neurodegeneration 17:1.
Crossref
Rosa De Micco, Sara Satolli, Mattia Siciliano, Antonio De Mase, Alfonso Giordano, Gioacchino Tedeschi & Alessandro Tessitore. (2021) Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study. Neurological Sciences 43:1, pages 357-364.
Crossref
Palanisamy Sivanandy, Tan Choo Leey, Tan Chi Xiang, Tan Chi Ling, Sean Ang Wey Han, Samantha Lia Anak Semilan & Phoon Kok Hong. (2021) Systematic Review on Parkinson’s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms. International Journal of Environmental Research and Public Health 19:1, pages 364.
Crossref
Carmen M. Labandeira, Maria G. Alonso Losada, Rosa Yáñez Baña, Maria I. Cimas Hernando, Iria Cabo López, Jose M. Paz González, Maria J. Gonzalez Palmás, Cristina Martínez Miró & Diego Santos García. (2021) Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR. Advances in Therapy 38:10, pages 5398-5411.
Crossref
Diego Santos García, Rosa Yáñez Baña, Carmen Labandeira Guerra, Maria Icíar Cimas Hernando, Iria Cabo López, Jose Manuel Paz González, Maria Gema Alonso Losada, Maria José Gonzalez Palmás, Carlos Cores Bartolomé & Cristina Martínez Miró. (2021) Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study. Journal of Personalized Medicine 11:8, pages 798.
Crossref
Inga Claus, Paul Muhle, Judith Czechowski, Sigrid Ahring, Bendix Labeit, Sonja Suntrup‐Krueger, Heinz Wiendl, Rainer Dziewas & Tobias Warnecke. (2021) Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease. Movement Disorders 36:8, pages 1815-1824.
Crossref
Mohammad Al Majali, Michael Sunnaa & Pratap Chand. (2021) Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease. Journal of Geriatric Psychiatry and Neurology 34:4, pages 263-273.
Crossref
Jayaprakash Sathish Kumar. (2021) In Silico Studies Comparing the Adjuvant Therapies Approved for Parkinson’s disease. Journal of Drug Delivery and Therapeutics 11:3-S, pages 104-110.
Crossref
Diego Santos García, Carmen Labandeira Guerra, Rosa Yáñez Baña, Maria Icíar Cimas Hernando, Iria Cabo López, Jose Manuel Paz Gonález, Maria Gemma Alonso Losada, María José González Palmás & Cristina Martínez Miró. (2021) Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study. Brain Sciences 11:3, pages 316.
Crossref
Esteban Peña, Carmen Borrué, Marina Mata, Juan Martínez-Castrillo, Araceli Alonso-Canovas, Juan Chico, Lydia López-Manzanares, Marcos Llanero, Jaime Herreros-Rodríguez, Alberto Esquivel, Teresa Maycas-Cepeda & Cristina Ruíz-Huete. (2021) Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study. Brain Sciences 11:2, pages 232.
Crossref
Rona R. Ramsay. 2021. Encyclopedia of Biological Chemistry III. Encyclopedia of Biological Chemistry III 249 260 .
Della G.T. Parambi. (2020) Treatment of Parkinson’s Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review. Combinatorial Chemistry & High Throughput Screening 23:9, pages 847-861.
Crossref
Ana Estela Ledesma, César Atilio Nazareno Catalán & Silvia Antonia Brandán. (2020) A combined theoretical and experimental study on the structure, vibrational, and electronic properties of antiparkinsonian drug safinamide. SN Applied Sciences 2:11.
Crossref
Inga Claus, Paul Muhle, Judith Suttrup, Bendix Labeit, Sonja Suntrup-Krueger, Rainer Dziewas & Tobias Warnecke. (2020) Predictors of Pharyngeal Dysphagia in Patients with Parkinson’s Disease. Journal of Parkinson's Disease 10:4, pages 1727-1735.
Crossref
Amira M El-Kosasy, Lobna A Hussein, Nesma M Mohamed & Nahla N Salama. (2020) New and validated RP-HPLC Method for Quantification of Safinamide Mesylate in Presence of Its Basic Degradate, Levodopa and Ondansetron: Application to Human Plasma. Journal of Chromatographic Science 58:9, pages 789-795.
Crossref
Javier Pagonabarraga, José Matías Arbelo, Francisco Grandas, Maria-Rosario Luquin, Pablo Martínez Martín, Mari Cruz Rodríguez-Oroz, Francesc Valldeoriola & Jaime Kulisevsky. (2020) A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sciences 10:3, pages 176.
Crossref
Pablo Duarte, Antonio Cuadrado & Rafael León. 2021. Reactive Oxygen Species. Reactive Oxygen Species 229 259 .
Pedro Merino. 2019. Chemical Biology of Neurodegeneration. Chemical Biology of Neurodegeneration 325 357 .
Martin Klietz, Stephan Greten, Florian Wegner & Günter U. Höglinger. (2019) Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients. Drugs & Aging 36:6, pages 511-530.
Crossref
Julie Cläre Nienstedt, Moritz Bihler, Almut Niessen, Rosemarie Plaetke, Monika Pötter‐Nerger, Christian Gerloff, Carsten Buhmann & Christina Pflug. (2018) Predictive clinical factors for penetration and aspiration in Parkinson's disease. Neurogastroenterology & Motility 31:3.
Crossref
Muthuraman Muthuraman, Nabin Koirala, Dumitru Ciolac, Bogdan Pintea, Martin Glaser, Stanislav Groppa, Gertrúd Tamás & Sergiu Groppa. (2018) Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease. Frontiers in Neurology 9.
Crossref
Paolo Pevarello & Mario Varasi. 2018. Successful Drug Discovery. Successful Drug Discovery 383 415 .
J. C. Nienstedt, C. Buhmann, M. Bihler, A. Niessen, R. Plaetke, C. Gerloff & C. Pflug. (2017) Drooling is no early sign of dysphagia in Parkinson′s disease. Neurogastroenterology & Motility 30:4.
Crossref
Francesca Mancini, Alessio Di Fonzo, Giulia Lazzeri, Linda Borellini, Vincenzo Silani, Marco Lacerenza & Cristoforo Comi. (2018) Real life evaluation of safinamide effectiveness in Parkinson’s disease. Neurological Sciences 39:4, pages 733-739.
Crossref
Fábio G. Teixeira, Miguel F. Gago, Paulo Marques, Pedro Silva Moreira, Ricardo Magalhães, Nuno Sousa & António J. Salgado. (2018) Safinamide: a new hope for Parkinson’s disease?. Drug Discovery Today 23:3, pages 736-744.
Crossref
Christina Pflug, Moritz Bihler, Katharina Emich, Almut Niessen, Julie Cläre Nienstedt, Till Flügel, Jana-Christiane Koseki, Rosemarie Plaetke, Ute Hidding, Christian Gerloff & Carsten Buhmann. (2017) Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early Stages: A Prospective Cohort Study. Dysphagia 33:1, pages 41-50.
Crossref
Andréia Cristina Karklin Fontana. 2018. Biochemical Approaches for Glutamatergic Neurotransmission. Biochemical Approaches for Glutamatergic Neurotransmission 169 225 .
Ana O. Pires, F.G. Teixeira, B. Mendes-Pinheiro, Sofia C. Serra, Nuno Sousa & António J. Salgado. (2017) Old and new challenges in Parkinson's disease therapeutics. Progress in Neurobiology 156, pages 69-89.
Crossref
S. Hagenow, A. Stasiak, R. R. Ramsay & H. Stark. (2017) Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B. Scientific Reports 7:1.
Crossref
Wolfgang H. Oertel. (2017) Recent advances in treating Parkinson’s disease. F1000Research 6, pages 260.
Crossref
Maria João Forjaz, Carmen Rodriguez-Blazquez & Pablo Martinez-Martin. 2017. Movement Disorders Curricula. Movement Disorders Curricula 165 180 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.